Skip to main content

Overcoming Limitations in Eye Care Therapies

Our technology, opens completely new and intriguing opportunities to cure, relief and prevent diseases in various areas of indications for patients.

Novaliq’s innovative EyeSol® technology is based on novel and exclusive water-free excipients.

It opens open completely new and intriguing opportunities to cure, relief and prevent diseases in various indications.

  • EyeSol® is a development platform for a novel drug category of ophthalmic topical therapies.

  • It opens open completely new and exciting opportunities in eye care for the relief and prevention of various ophthalmological disease.

  • EyeSol® products are beneficial to the ocular surface, micro-dosed and non-preserved.

  • Two EyeSol® products are approved by US FDA for the treatment of signs and symptoms of dry eye disease.

  • EyeSol® substances are highly biocompatible and do not accumulate in human tissues

  • The technology platform is proprietary to Novaliq and IP protected.

  • Our vision is to revolutionize ocular treatments to realize the full potential of topical eye care treatments.

EyeSol® benefits for topical ocular applications:

For our products we only use highly pure substances and raw materials from qualified manufacturers. We have extensively tested and proven their safety, efficacy and tolerability in close cooperation with the regulatory authorities. EyeSol products to treat dry eye disease are approved and on the market in the USA, Europe, Australia, New Zealand and China. All products are successfully partnered with leading parties worldwide.

Novaliq’s semifluorinated alkanes (SFAs) have been preclinically, clinically and ecotoxicologically tested. SFAs are not metabolized in the human body. Furthermore, they are physically, chemically, and physiologically inert with an excellent biocompatibility and a very good safety profile.

Learn more

Human safety has further been confirmed in clinical trials conducted around the world and is supported by market data from > 20 million of units sold including the medical devices (NovaTears®/ EvoTearsTM / NovaTears®+omega-3) and medicinal products (MieboTM Heng Qin™, Vevye® and Vevizye®)